title: Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China.
abstract: OBJECTIVE
  To assess the cost-effectiveness of infliximab-containing therapy (ICT) for moderate-to-severe rheumatoid arthritis (RA) in a medium-sized Chinese city.
  
  
  METHODS
  A Chinese prospective cohort study comparing ICT (25 patients) versus conventional disease-modified antirheumatic drugs (24 patients) for RA was used to assess the cost-effectiveness of ICT.
  
  
  RESULTS
  The cohort study observed significantly reduced disease activity score of 28 joints (coefficient -2.718, p < 0.001), improved EQ-5D (coefficient 0.453, p < 0.001) and increased medical costs (coefficient 1.289, p < 0.001) associated with ICT. The incremental cost-effectiveness ratio per gained quality-adjusted life year for ICT versus disease-modified antirheumatic drugs was 1.897-times of the local gross domestic product per capita.
  
  
  CONCLUSIONS
  Infliximab was a favorable cost-effective alternative option for moderate-to-severe RA in a medium-sized city of China.
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Jingyang
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Wen
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Anlie
authors.initials: A
authors.lastname: Cai
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Tian
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Luo
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Deng
authors.affiliation: Department of Rheumatology & Immunology, Zhuzhou Hospital of Xiangya Medical School, the Central South University, Hunan, China.
authors.forename: Jingyun
authors.initials: J
authors.lastname: He
authors.affiliation: Health Economics, Xian Janssen, Beijing, China.
authors.forename: Yicheng
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Health Economics and Outcomes Research, Normin Health Changsha Representative Office, Changsha, China.
authors.forename: Wendong
authors.initials: W
authors.lastname: Chen
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002681:China; D015331:Cohort Studies; D003362:Cost-Benefit Analysis / Q000191:economics* / Q000379:methods; D006801:Humans; D000069285:Infliximab / Q000191:economics* / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D014505:Urban Population
chemical_list: D018501:Antirheumatic Agents; D000069285:Infliximab
keywords: China; cost–effectiveness; infliximab; rheumatoid arthritis